Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Dear Sir, A 61-year-old male with Crohn's disease (CD) compromising jejunum and terminal ileum managed with mesalamine, azathioprine and infliximab. Ever since 2009 our patient has presented a tortuous evolution based on multiple episodes of active CD, acute diverticulitis, Clostridium difficile infection (CDI) and bacteremia for multidrug-sensitive Escherichia coli (MDSEC) (Fig. 1). On September 2009 the patient presented fever, after a thorough work-up was done to exclude primary infection sources, bacteremia was confirmed for MDSEC. Treatment consisted in antibiotics (quinolones–cephalosporins) with symptom resolution, similar in the 5 episodes. In August 2010, CDI was confirmed by A toxin and image of pseudomembranous colitis. We started a 14-day treatment with oral vancomycin with positive clinical response. The third episode, presented a positive clinical course with the same regimen however he relapsed on the third day after treatment. Tapered oral vancomycin was used with satisfactory response. In January 2013, our patient presented CDI that was managed with vancomycin with initial good response but relapsing on the fourth day after treatment. The patient had severe symptoms and required admission (i.v. metronidazole and oral vancomycin). On the third day with no response, we decided to perform Fecal Microbiota Transplantation (FMT) through a colonoscopy. An exhaustive screening was done in donor's blood and stool samples to rule out concomitant pathologies. Infliximab was discontinued 6 weeks before FMT, azathioprine five days before and antibiotics 24 h before. Twenty-four hours after FMT, the patient presented high fever (T° 39 °C) and positive blood cultures for MDSEC strain. Bacteremia was treated with aztreonam (5 days) with excellent clinical and laboratory response. At 5-month follow-up the patient is completely asymptomatic and PCR for C. difficile is negative. Microbial dysbiosis plays a fundamental role in the pathogenesis of inflammatory bowel disease (IBD) and CDI. Recent studies have shown that FMT indices a remarkable change of the microbiota and is an effective alternative in RCDI with > 90% success rate1. Patients with IBD present a higher risk for CDI, even in the absence of antibiotics use2. CDI is a proven factor of relapse and refractoriness of IBD, increasing their morbidity and mortality. There is insufficient information about adverse effects of TMF, most of them are gastrointestinal3. To our knowledge this is the first report on bacteremia associated to FMT and maybe altered intestinal permeability due to CD could favor it4. Since bacteremia is treated with antibiotics the occurrence of this complication might have had a deleterious effect but aztreonam was chosen because it should have no effect on the anaerobic flora, avoiding a potential counteract action over FMT. In conclusion, FMT is a viable treatment for patients with RCDI after failure of conventional therapies, but complications exist and bacteremia should be considerate.5 All the authors declare that there is no conflict of interest and that no financial support has been received. Temporal evolution of episodes of bacteremia, infection for Clostridium difficile, diverticulitis and surgery for Crohn's disease. FMT: fecal microbiota transplantation. E. coli: Escherichia coli.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kunde, S., Pham, A., Bonczyk, S., Crumb, T., Duba, M., Conrad, H., Cloney, D., & Kugathasan, S. (2013) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318292fa0d · Cited by 314
Cited by
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
DeFilipp, Z., Bloom, P. P., Torres Soto, M., Mansour, M. K., Sater, M. R. A., Huntley, M. H., Turbett, S., Chung, R. T., Chen, Y.-B., & Hohmann, E. L. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910437 · Cited by 1,281
Shen, Z.-H., Zhu, C.-X., Quan, Y.-S., Yang, Z.-Y., Wu, S., Luo, W.-W., Tan, B., & Wang, X.-Y. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i1.5 · Cited by 646
Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer
Fong, W., Li, Q., & Yu, J. (2020) · Oncogene · doi:10.1038/s41388-020-1341-1 · Cited by 613
Fecal microbiota transplantation: Review and update
Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., & Wu, D.-C. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.08.011 · Cited by 576
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Metadata
- Authors
- Quera, R., Espinoza, R., Estay, C., & Rivera, D.
- Venue
- Journal of Crohn's and Colitis
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03
- Volume
- 8
- Issue
- 3
- Pages
- 252-253
- ISSN
- 1873-9946 (ISSN-L)
- OpenAlex
- W2130081368
- Cited by
- 156
- References
- 1
- FWCI
- 12.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. https://app.cochat.ai/papers/10.1016/j.crohns.2013.10.002
- The paper
- Quera, R., Espinoza, R., Estay, C., & Rivera, D. (2014). Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection. Journal of Crohn's and Colitis. https://doi.org/10.1016/j.crohns.2013.10.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.